创新药齐涨！康方生物市值破千亿

Core Viewpoint - Multiple favorable policies have been released, leading to a collective surge in innovative drug stocks, with Kangfang Biotech's market capitalization surpassing HKD 100 billion [9][14]. Market Performance - On July 4, the Hang Seng Index experienced a decline of 0.64%, closing at 23,916.06 points, with a weekly drop of 1.52% [1]. - The Hang Seng Biotechnology Index rose by 1.07%, indicating resilience in the biotech sector despite broader market declines [15]. - The total market turnover was HKD 267.8 billion, with net inflows from southbound funds amounting to HKD 6.68 billion [3]. Stock Performance - Notable gainers included: - Xinyi Solar, up 4.73% [4] - China Biologic Products, up 2.75% [4] - Hansoh Pharmaceutical, up 2.47% [4] - Kangfang Biotech's stock price increased by 9.43% to HKD 116.10, with a total market value reaching HKD 104.2 billion [10][13]. Policy Impact on Innovative Drugs - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, which positively impacted stock prices in the sector [17]. - The introduction of a commercial insurance directory for innovative drugs is expected to expand market opportunities and encourage pharmaceutical companies to enhance R&D efforts [18]. Company Highlights - Kangfang Biotech's first dual-antibody ADC drug, AK146D1, has entered clinical trials, marking a significant milestone for the company [13]. - The company is recognized as the only global entity with two tumor immunotherapy dual antibodies, establishing a leading advantage in the IO+ADC landscape [13].